Company:  EXELIXIS, INC. (EXEL)
Form Type:  8-K
Filing Date:  5/10/2022 
CIK:  0000939767 
Address:  1851 HARBOR BAY PARKWAY 
City, State, Zip:  ALAMEDA, California 94502 
Telephone:  (650) 837-7000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$17.29  
Change: 
0.00 (0.00%)  
Trade Time: 
Feb 07  
Market Cap: 
$5.58B
Trade EXEL now with

© 2023  
Description of Business
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, including our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics. Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S.
Register and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02. Results of Operations and Financial Condition.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1
    INCOME STATEMENT


EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.